Isolated annuloplasty in elderly patients with secondary mitral valve regurgitation: short- and long-term outcomes with a less invasive approach.
annuloplasty
elderly
heart failure
less and minimally invasive mitral valve surgery
secondary mitral valve regurgitation
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
03
2023
accepted:
06
09
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
Long-term outcomes of elderly and frail patients with secondary mitral valve regurgitation (MR) are inconclusive. Especially in patients with co-morbidities such as atherosclerosis who are suffering from heart failure, optimal medical therapy (OMT) is the preferred therapy relative to surgical or percutaneous interventions. It remains challenging to identify the most successful therapy to improve symptoms and increase life expectancy. To reduce surgical trauma for these patients, minimally invasive mitral valve surgery (MIMVS) was developed; this has shown promising medium-term results, but there is still a lack of evidence regarding long-term results. The aim of this investigation was to describe the long-term outcomes of less invasive mitral valve surgery (MVS) in elderly patients. In this longitudinal retrospective analysis, 67 patients (aged ≥70 years) with secondary MR who underwent MV repair ± tricuspid valve repair (TVR) were identified. MVS was performed via minithoracotomy (MT) in most cases ( The median age of patients (62.7% female) was 74 years (interquartile range: 72-76 years), with a median EuroSCORE2 of 2.8% (1.5%-4.6%) and N-terminal pro-brain natriuretic peptide plasma levels of 1,434 ng/L (1035-2149 ng/L). The median follow-up period was 5.6 years (2.7-8.5 years). The reoperation-free long-term survival rate up to 10 years was 66.2%. Combined operative success and perioperative safety were achieved in 94% and 76% of patients, respectively. Additional TVR was performed in 56.7% of patients, without any significant difference in survival rates compared to the group without TVR ( Less invasive MV repair for secondary MR shows excellent operative success and safety in selected patients. Freedom from significant MR and from the need for reoperation indicates long-lasting efficacy. These results should be considered in heart team discussions regarding allocation of patients to surgical mitral procedures.
Sections du résumé
Background
UNASSIGNED
Long-term outcomes of elderly and frail patients with secondary mitral valve regurgitation (MR) are inconclusive. Especially in patients with co-morbidities such as atherosclerosis who are suffering from heart failure, optimal medical therapy (OMT) is the preferred therapy relative to surgical or percutaneous interventions. It remains challenging to identify the most successful therapy to improve symptoms and increase life expectancy. To reduce surgical trauma for these patients, minimally invasive mitral valve surgery (MIMVS) was developed; this has shown promising medium-term results, but there is still a lack of evidence regarding long-term results. The aim of this investigation was to describe the long-term outcomes of less invasive mitral valve surgery (MVS) in elderly patients.
Methods
UNASSIGNED
In this longitudinal retrospective analysis, 67 patients (aged ≥70 years) with secondary MR who underwent MV repair ± tricuspid valve repair (TVR) were identified. MVS was performed via minithoracotomy (MT) in most cases (
Results
UNASSIGNED
The median age of patients (62.7% female) was 74 years (interquartile range: 72-76 years), with a median EuroSCORE2 of 2.8% (1.5%-4.6%) and N-terminal pro-brain natriuretic peptide plasma levels of 1,434 ng/L (1035-2149 ng/L). The median follow-up period was 5.6 years (2.7-8.5 years). The reoperation-free long-term survival rate up to 10 years was 66.2%. Combined operative success and perioperative safety were achieved in 94% and 76% of patients, respectively. Additional TVR was performed in 56.7% of patients, without any significant difference in survival rates compared to the group without TVR (
Conclusion
UNASSIGNED
Less invasive MV repair for secondary MR shows excellent operative success and safety in selected patients. Freedom from significant MR and from the need for reoperation indicates long-lasting efficacy. These results should be considered in heart team discussions regarding allocation of patients to surgical mitral procedures.
Identifiants
pubmed: 37915742
doi: 10.3389/fcvm.2023.1193156
pmc: PMC10617676
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1193156Informations de copyright
© 2023 Oezpeker, Hoefer, Barbieri, Gollmann-Tepekoeylue, Johannes, Clemens, Suat, Adel, Sasa, Mueller, Grimm and Bonaros.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor TF declared a past co-authorship with the author NB.
Références
Int J Cardiol. 2017 Oct 1;244:235-241
pubmed: 28624330
J Cardiovasc Dev Dis. 2023 Jan 11;10(1):
pubmed: 36661923
Eur J Cardiothorac Surg. 2021 Apr 29;59(4):863-868
pubmed: 33313790
J Thorac Cardiovasc Surg. 2023 Jun;165(6):2037-2046.e4
pubmed: 34446288
J Clin Med. 2022 Feb 10;11(4):
pubmed: 35207197
Circulation. 2010 Mar 2;121(8):973-8
pubmed: 20159833
Interact Cardiovasc Thorac Surg. 2022 Nov 8;35(6):
pubmed: 36130272
Dtsch Arztebl Int. 2017 Nov 17;114(46):777-784
pubmed: 29229038
Eur Heart J. 2018 Jan 1;39(1):39-46
pubmed: 29020337
Thorac Cardiovasc Surg. 2019 Oct;67(7):524-530
pubmed: 30180258
Aging Clin Exp Res. 2021 Nov;33(11):3047-3056
pubmed: 33813686
J Am Coll Cardiol. 2021 Feb 2;77(4):450-500
pubmed: 33342587
ASAIO J. 2021 Oct 1;67(10):1139-1147
pubmed: 34570728
Eur J Cardiothorac Surg. 2022 Feb 18;61(3):637-644
pubmed: 34738105
J Am Coll Cardiol. 2015 Mar 31;65(12):1231-1248
pubmed: 25814231
Open Heart. 2021 Apr;8(1):
pubmed: 33911022
Ann Thorac Surg. 2012 Dec;94(6):1999-2003
pubmed: 22835550
Braz J Cardiovasc Surg. 2021 Feb 01;36(1):1-9
pubmed: 33113315
Ann Cardiothorac Surg. 2021 Jan;10(1):66-74
pubmed: 33575177
Int J Surg. 2016 Sep;33 Pt A:164-71
pubmed: 27131758
Heart Lung Circ. 2021 Mar;30(3):431-437
pubmed: 32896484
Heart. 2011 Oct;97(20):1675-80
pubmed: 21807656
Ann Thorac Cardiovasc Surg. 2022 Oct 20;28(5):342-348
pubmed: 35851568
AsiaIntervention. 2020 Dec;6(2):77-84
pubmed: 34912990
JACC Heart Fail. 2017 Sep;5(9):652-659
pubmed: 28859754
J Thorac Cardiovasc Surg. 2017 Jan;153(1):108-115
pubmed: 27665221
Interact Cardiovasc Thorac Surg. 2015 Dec;21(6):748-53
pubmed: 26403175
Medicine (Baltimore). 2016 Jun;95(25):e3938
pubmed: 27336886
Biomed Res Int. 2014;2014:736298
pubmed: 24812629
Medicina (Kaunas). 2021 Oct 30;57(11):
pubmed: 34833397
J Thorac Dis. 2018 Jul;10(7):4540-4555
pubmed: 30174907
J Am Coll Cardiol. 2021 Aug 31;78(9):895-897
pubmed: 34446161
Circulation. 2013 Nov 19;128(21):2333-43
pubmed: 24249619
Ann Thorac Surg. 2007 Jan;83(1):77-82
pubmed: 17184634
J Cardiothorac Surg. 2022 Sep 16;17(1):236
pubmed: 36114506
Expert Rev Cardiovasc Ther. 2017 Jan;15(1):15-24
pubmed: 27905211
Ann Cardiothorac Surg. 2013 Nov;2(6):853-4
pubmed: 24349996
Eur J Cardiothorac Surg. 2019 Jun 1;55(Suppl 1):i17-i25
pubmed: 31106337
Ann Cardiothorac Surg. 2021 Jan;10(1):1-14
pubmed: 33575171
N Engl J Med. 2020 Oct 8;383(15):1458-1467
pubmed: 33027570
Am J Cardiol. 2003 Mar 1;91(5):538-43
pubmed: 12615256
JAMA. 2021 Jun 8;325(22):2309-2310
pubmed: 34100880
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165
J Am Coll Cardiol. 2022 May 3;79(17):1757-1780
pubmed: 35379504
J Am Coll Cardiol. 2005 Feb 1;45(3):381-7
pubmed: 15680716
J Am Coll Cardiol. 2022 Dec 13;80(24):2314-2330
pubmed: 36480974
Ann Cardiothorac Surg. 2021 Jan;10(1):75-84
pubmed: 33575178